Multidimensional Analysis of Treatment Adherence in Patients with Multiple Chronic Conditions. A Cross-sectional Study in a Tertiary Hospital
Overview
Nursing
Authors
Affiliations
Objective: Determine treatment adherence in patients with multiple chronic conditions (MCC).
Methods: A random patient sample ≥ 15 years, discharged from hospital with ≥1 chronic conditions (CC) was interviewed after 6-12 months. Analysis included variables in 5 dimensions (WHO): socio-demographics, disease, treatment, patient and health system characteristics. Morisky-Green adherence questionnaire was used. High chronic treatment complexity was defined as: >3 pills/day, >6 inhalations/day, >1 injection/day, pharmacological treatment plus diet or self-monitoring techniques.
Results: 301 patients were interviewed (62 ± 15 years, 59% males). Despite good treatment information perception (79%), only 3% followed the patient education programme. Poor adherents (82%) were older (64 ± 14 years vs. 55 ± 16 years), had more CC (3.25 ± 2.02 vs. 2.62 ± 2.72), a higher frequency of hypertension (44% vs. 15%), ischaemic heart diseases: (21% vs. 4%), hyperlipidaemia (19% vs. 6%), more pills/day (5.78 ± 4.14 vs. 3.20 ± 4.70) and more complex treatments (95% vs. 70%) (p<0.05). On multivariate analysis number of CC [3.68 (0.75-18.15)], pills/day [2.23 (1.02-4.84)], treatment complexity [4.00 (1.45-11.04)], and hypertension [2.57 (1.06-6.25)] were predictive of poor adherence (OR 95% CI p<0.05).
Conclusion: The WHO conceptual framework allows the construction of poor adherence risk profiles in patients with MCC after hospital discharge.
Practice Implications: Predictive variables of poor adherence could help clinicians detect patients with MCC most likely to present poor adherence.
Witts W, Amu H, Kwafo F, Angaag N, Bain L PLoS One. 2024; 19(9):e0308402.
PMID: 39241027 PMC: 11379372. DOI: 10.1371/journal.pone.0308402.
Karimi M, Mofidi Nejad M, Tabaeifard R, Omid N, Rezaei Z, Azadbakht L Sci Rep. 2024; 14(1):19681.
PMID: 39181929 PMC: 11344835. DOI: 10.1038/s41598-024-70162-7.
Optimization of Therapy in Patients with Epilepsy and Psychiatric Comorbidities: Key Points.
Pisani F, Rosa Pisani L, Barbieri M, De Leon J, Spina E Curr Neuropharmacol. 2022; 21(8):1755-1766.
PMID: 35619263 PMC: 10514544. DOI: 10.2174/1570159X20666220526144314.
Dehghan M, Nayeri N Int J Hypertens. 2021; 2021:6617980.
PMID: 33824763 PMC: 8007347. DOI: 10.1155/2021/6617980.
Peh K, Kwan Y, Goh H, Ramchandani H, Phang J, Lim Z J Gen Intern Med. 2021; 36(9):2784-2795.
PMID: 33660211 PMC: 8390603. DOI: 10.1007/s11606-021-06648-1.